Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine
Source abstract
Abstract
Abstract Tumor vaccines have made a significant breakthrough in clinical trials of cancer therapy, but have shown limited efficacy. Herein, we develop a novel tumor vaccine delivery strategy through a biodegradable microneedle patch (MN), which allows sustained release of tumor antigen and induces long term anti-tumor response. A tumor antigen peptide (OVA257–264: SIINFEKL) was fused with hepatitis B core (HBc) protein virus like particles (OVA-HBc VLPs) to increase the immunogenicity of tumor antigen. Mesoporous silica nanoparticles (MSN) were adopted as a vaccine adjuvant for enhancing the function of dendritic cells (DCs). OVA-HBc VLPs and MSN were capsulated into microneedles together [MSN/OVA-HBc@MN]. MSN/OVA-HBc@MN could significantly stimulate DC maturation and increase the presentation of OVA on DCs in vitro. MSN/OVA-HBc@MN can effectively stimulate antigen specific anti-tumor immune response and be used as prophylactic vaccines to effectively inhibit tumor formation. Moreover, the addition of CpG-DNA can enhance the therapeutic effect of MSN/OVA-HBc@MN in distant tumors and long term immune memory effect. Our results thus demonstrate that MSN- CpG/OVA-HBc@MN could be as a potential tumor-specific vaccination platform for tumor therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Advancements in Transdermal Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Towards personalized, tumour-specific, therapeutic vaccines for cancer10.1038/nri.2017.131 ↗
2. Improving vaccine and immunotherapy design using biomaterials10.1016/j.it.2017.10.002 ↗
3. The dawn of vaccines for cancer prevention10.1038/nri.2017.140 ↗
4. Nanoparticle vaccines against infectious diseases10.3389/fimmu.2018.02224 ↗
5. Neoantigens in cancer immunotherapy10.1126/science.aaa4971 ↗
6. Efficient encapsulation of Fe3O4 nanoparticles into genetically engineered hepatitis B core virus-like particles through a specific interaction for potential bioapplications10.1002/smll.201401952 ↗
7. Three-dimensional structure of hepatitis b virus core particles determined by electron cryomicroscopy10.1016/0092-8674(94)90142-2 ↗
8. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins10.1074/jbc.M805211200 ↗
9. HBv core particles as a carrier for B cell/T cell epitopes10.1159/000050037 ↗
10. Improving immunogenicity and safety of flagellin as vaccine carrier by high-density display on virus-like particle surface10.1016/j.biomaterials.2020.120030 ↗
11. Virus-based nanocarriers for drug delivery10.1016/j.addr.2012.01.005 ↗
12. Improved stable indocyanine green (ICG)-mediated cancer optotheranostics with naturalized hepatitis B core particles10.1002/adma.201707567 ↗
13. Nanocage encapsulation improves antiepileptic efficiency of phenytoin10.1016/j.biomaterials.2020.119849 ↗
14. Bioengineered nanocage from HBc protein for combination cancer immunotherapy10.1021/acs.nanolett.8b04722 ↗
15. Interaction of the hepatitis B core antigen and the innate immune system10.4049/jimmunol.0803683 ↗
16. Dual-antigen-loaded hepatitis B virus core antigen virus-like particles stimulate efficient immunotherapy against melanoma10.1021/acsami.0c16012 ↗
17. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles10.1038/s41467-020-16639-1 ↗
18. Translating tumor antigens into cancer vaccines10.1128/CVI.00286-10 ↗
19. Immunization without needles10.1038/nri1728 ↗
20. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination10.1016/j.drudis.2011.07.004 ↗
21. Effect of microneedle design on pain in human volunteers10.1097/AJP.0b013e31816778f9 ↗
22. Progress and perspective of microneedle system for anti-cancer drug delivery10.1016/j.biomaterials.2020.120410 ↗
23. Transdermal drug delivery10.1038/nbt.1504 ↗
24. Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity10.1016/j.biomaterials.2020.120491 ↗
25. Microneedle, bio-microneedle and bio-inspired microneedle: a review10.1016/j.jconrel.2017.02.011 ↗
26. Transdermal immunomodulation: principles, advances and perspectives10.1016/j.addr.2018.03.010 ↗
27. Drug-free, nonsurgical reduction of intraocular pressure for four months after suprachoroidal injection of hyaluronic acid hydrogel10.1002/advs.202001908 ↗
28. Construction of microneedle-assisted co-delivery platform and its combining photodynamic/immunotherapy10.1016/j.jconrel.2020.05.006 ↗
29. Rapidly detachable microneedles using porous water-soluble layer for ocular drug delivery10.1002/admt.201901145 ↗
30. A Two-dimensional MXene potentiates a therapeutic microneedle patch for photonic implantable medicine in the second nir biowindow10.1039/D0NR01444C ↗
31. Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design10.1016/j.actbio.2017.11.004 ↗
32. Diphtheria toxoid and N-trimethyl chitosan layer-by-layer coated pH-sensitive microneedles induce potent immune responses upon dermal vaccination in mice10.1016/j.jconrel.2017.07.017 ↗
33. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type i interferons10.1016/j.immuni.2016.02.004 ↗
34. Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery10.1039/c3nr00357d ↗
35. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy
36. Mesoporous silica hollow spheres with ordered radial mesochannels by a spontaneous self-transformation approach10.1021/cm303338v ↗
37. Ordered mesoporous molecular-sieves synthesized by a liquid-crystal template mechanism10.1038/359710a0 ↗
38. Enhancing cancer immunotherapy with nanomedicine10.1038/s41577-019-0269-6 ↗
39. Skin infection generates non-migratory memory CD8+ T-RM cells providing global skin immunity10.1038/nature10851 ↗
40. Characterising the material properties at the interface between skin and a skin vaccination microprojection device10.1016/j.actbio.2016.02.039 ↗
41. Biomaterial-assisted targeted modulation of immune cells in cancer treatment10.1038/s41563-018-0147-9 ↗
42. Vaccine Adjuvants: putting Innate Immunity to Work10.1016/j.immuni.2010.10.002 ↗
43. Recent progress concerning CpG DNA and its use as a vaccine adjuvant10.1586/14760584.2014.863715 ↗
44. Key roles of adjuvants in modern vaccines10.1038/nm.3409 ↗
45. Virus-induced humoral immunity: on how B cell responses are initiated10.1016/j.coviro.2013.05.004 ↗
46. Using immunotherapy to boost the abscopal effect10.1038/nrc.2018.6 ↗